AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. PT.
A live audio webcast will be available via the company's Investor Relations Events & Presentations page and a replay will be posted after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RCEL gained 2.98%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Medical Devices show mixed moves, with some gains (e.g., ICAD +3.48%) and declines (e.g., RPID -4.57%), suggesting RCEL’s slight -1.8% move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Conference appearance | Neutral | +0.0% | Piper Sandler healthcare conference presentation and webcast access. |
| Nov 09 | Investor outreach | Positive | +5.3% | Investor webinar briefing following Q3 2025 earnings webcast. |
| Nov 06 | Earnings results | Negative | -2.9% | Q3 2025 results with revenue decline and lowered full-year guidance. |
| Nov 03 | Clinical data update | Positive | -2.3% | Data reinforcing RECELL as standard of care in acute wound treatment. |
| Oct 29 | Earnings pre-announcement | Neutral | +0.8% | Scheduling and access details for Q3 2025 earnings call. |
Recent AVITA announcements on conferences and clinical data often saw modest or negative price reactions, while investor-focused communications like webinars drew stronger positive responses.
Over the past few months, AVITA has combined financial updates with active investor outreach. Earnings on Nov 6, 2025 showed lower commercial revenue and reduced full-year guidance, with a -2.86% reaction. Strong clinical data on Nov 3, 2025 still coincided with a -2.33% move. In contrast, an investor webinar on Nov 9, 2025 saw a +5.31% move. Prior conference announcements on Oct 29 and Nov 24 had minimal impact. Today’s J.P. Morgan conference appearance fits this pattern of ongoing visibility efforts.
Market Pulse Summary
This announcement highlights AVITA’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, reinforcing ongoing efforts to engage investors and the broader healthcare community. Recent history shows mixed market responses to conferences, earnings, and clinical updates, including moves of -2.33%, -2.86%, and +5.31%. Investors may watch for any new information shared at the event and how it relates to prior financial and clinical disclosures.
AI-generated analysis. Not financial advice.
VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When will AVITA Medical (RCEL) present at the J.P. Morgan Healthcare Conference?
How can investors listen to AVITA Medical (RCEL) CEO Cary Vance's presentation on January 14, 2026?
Will a replay of the AVITA Medical (RCEL) J.P. Morgan presentation be available?
What is the exact event and session for RCEL at the January 2026 J.P. Morgan conference?
Where is the AVITA Medical (RCEL) webcast hosted for the January 14, 2026 presentation?
Is the AVITA Medical (RCEL) presentation at J.P. Morgan expected to include financial guidance or clinical data?
